Acquired resistance to immune checkpoint inhibitors Review


Authors: Schoenfeld, A. J.; Hellmann, M. D.
Review Title: Acquired resistance to immune checkpoint inhibitors
Abstract: Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple tumor types, providing unprecedented survival in some patients. Despite the characteristic durability of response to ICI, unfortunately many patients with initial response will later develop acquired resistance. The current understanding of mechanisms of acquired resistance to ICIs is remarkably limited, perhaps restraining effective development of next-generation immunotherapies. Here, we examine the barriers to progress and emerging clinical reports interrogating acquired resistance with the goal to facilitate efforts to overcome acquired resistance to ICIs in the future. © 2020 Elsevier Inc. Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple tumor types, providing unprecedented survival in some patients. Despite the characteristic durability of response to ICI, unfortunately many patients with initial response will later develop acquired resistance. The current understanding of mechanisms of acquired resistance to ICIs is remarkably limited, perhaps restraining effective development of next-generation immunotherapies. Here, we examine the barriers to progress and emerging clinical reports interrogating acquired resistance with the goal to facilitate efforts to overcome acquired resistance to ICIs in the future. © 2020 Elsevier Inc.
Keywords: review; immunotherapy; acquired resistance; human; icis
Journal Title: Cancer Cell
Volume: 37
Issue: 4
ISSN: 1535-6108
Publisher: Cell Press  
Date Published: 2020-04-13
Start Page: 443
End Page: 455
Language: English
DOI: 10.1016/j.ccell.2020.03.017
PUBMED: 32289269
PROVIDER: scopus
PMCID: PMC7182070
DOI/URL:
Notes: Review -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Matthew David Hellmann
    412 Hellmann